Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 659 of 6351
-
RNA vaccine fights childhood cancers in new trial
Disease control OngoingThe Investigators have demonstrated in preclinical studies that RNA liposomes activate APCs, induce antigen-specific T cell immunity, and can supplant DCs in a cell therapy model for HGG and have shown feasibility and activity of this approach in preclinical models and in canine …
Phase 1/2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for colorectal cancer: experimental combo trial launches
Disease control Recruiting nowThe main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New pill could bring relief to eczema sufferers
Disease control By invitation onlyTo evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).
Phase 3 • Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:45 UTC
-
New radiation boost aims to fight pancreatic cancer
Disease control Recruiting nowThe goal of this clinical trial is to test the effect of high-dose radiation therapy after initial chemotherapy in patients with locally advanced pancreatic cancer. The main question it aims to answer is: • For patients with locally advanced pancreatic cancer that responded to i…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New obesity drug shows promise in major trial
Disease control OngoingThe primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo aims to stop Triple-Negative breast cancer recurrence
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacity and safety of pembrolizumab and capecitabine on the invasive disease-free survival, in participants who have triple negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy associated with pem…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Blood test may spot lung cancer without a needle biopsy
Diagnosis Recruiting nowInvestigators aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, investigators will investigate the p…
Sponsor: National Taiwan University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
New study aims to prevent suicide in vulnerable teens
Knowledge-focused Recruiting nowSuicide is one of the main causes of death among teenagers. Because it is preventable, primary prevention of suicide has become a public health priority, with encouraging results in promoting suicide awareness and reducing suicidal thoughts among adolescents. However, the lack of…
Sponsor: Stephanie Baggio • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New combo therapy aims to supercharge immune cells against tough melanoma
Disease control Recruiting nowA Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.
Phase 1/2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Off-the-Shelf cell therapy takes on tough lymphoma
Disease control Recruiting nowThis is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.
Sponsor: Bioray Laboratories • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a digital battery sharpen detection of brain injury aftermath?
Diagnosis Recruiting nowThe management of head trauma patients requires the assessment of cognitive disorders using standardized neuropsychological tests and questionnaires. However, the evaluation tools currently available present well-identified limitations limiting the accuracy of the measurements (i…
Sponsor: Direction Centrale du Service de Santé des Armées • Aim: Diagnosis
Last updated Aug 30, 2026 00:00 UTC
-
New vaccine-like therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowResearchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New gout drug shows promise in major trial
Disease control OngoingThis study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Phase 3 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New TB cocktails aim to speed up recovery
Disease control Recruiting nowA5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB). A5409 hypothesizes that novel regimens…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New lung cancer combo aims to outperform current standard in consolidation therapy
Disease control Recruiting nowThis is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evalu…
Phase 2 • Sponsor: SCRI Development Innovations, LLC • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Mind-Body approach ease chronic vulvar pain?
Symptom relief OngoingThe purpose of this project is to develop and evaluate a multimodal treatment for provoked vulvodynia, by addressing the following specific research questions: 1. What is the feasibility and acceptability of this multimodal treatment protocol? 2. What are the effects on pain and…
Sponsor: Karlstad University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New pill could stop Period-Linked migraines before they start
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy duo aims to shrink stomach tumors before surgery
Disease control Recruiting nowTo explore the efficacy of Iparomlimab and Tuvonralimab (QL1706) in combination with SOX chemotherapy versus chemotherapy alone for the neoadjuvant treatment of locally-progressed gastric/gastroesophageal union adenocarcinomas by evaluating the complete pathologic remission rate …
Phase 2 • Sponsor: Shandong Provincial Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Promising new radiation therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThe main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy aims to stop cervical cancer return
Disease control Recruiting nowEfficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Phase 2 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC